New Drug For Melanoma Shows Positive Results In Early Clinical Trial
Apr 17th 2008Drug InformationDermatology
Rutgers Professor Suzie Chen has found that riluzole, a U.S. Food and Drug Administration (FDA) approved drug used to treat Lou Gehrig’s disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.A Phase 0 (zero) clinical trial of riluzole (brand name Rilutek), conducted by James Goydos, a surgical oncologist with The Cancer Institute of New Jersey (CINJ), is in process with a small group of late-stage (stage 3 or 4) melanoma patients.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
